Cagrilintide (10 mg)

Discover the advanced solution of premium Cagrilintide. Each 3 ml clear glass vial contains 10 mg of high-purity, lyophilized Cagrilintide, meticulously formulated for reliable performance. The precision-sealed vial ensures stability and integrity, while the easy-to-use, white freeze-dried powder. Ideal for professionals seeking accuracy and consistency, this product reflects Aminova's commitment to innovation and quality. Best as an appetite suppressant/craving control to your GLP-1.

Benefits of Cagrilintide:

Weight loss

• Enhances satiety: Cagrilintide helps people feel full faster and for longer, which leads to reduced food intake and fewer cravings.

• Reduces appetite: It influences the brain regions that control appetite, leading to less hunger.

• Delays gastric emptying: By slowing down how quickly the stomach empties, it helps prolong the feeling of fullness.

• Significant weight reduction: As a monotherapy, studies have shown cagrilintide can lead to a clinically meaningful reduction in body weight. 

Blood sugar control

• Improved glycemic control: As an amylin analog, cagrilintide helps regulate post-meal blood glucose levels, benefiting those with prediabetes and type 2 diabetes.

• Suppresses glucagon: It helps control blood sugar by suppressing glucagon, a hormone that raises blood glucose. 

Combination therapy with semaglutide, tirzepatide, retatrutide (CagriSema, CagriTirz, CagriReta)

While cagrilintide is effective on its own, it has shown particularly powerful results when combined with semaglutide (a GLP-1 receptor agonist) into a single co-formulation. 

• Greater weight loss: Studies have shown that Cagrilintide combined with GLP-1 leads to greater weight reduction than either medication alone. In one phase 3 trial, participants achieved a mean body weight reduction of over 20%.

• Synergistic mechanisms: The two drugs have complementary mechanisms of action. Semaglutide, Tirzepatide, Retatrutide acts on GLP-1 receptors, and cagrilintide acts on amylin receptors. Both influence appetite, but through different pathways, leading to a more comprehensive effect on weight and metabolic health.

• Broad metabolic improvements: The combination therapy has been shown to improve cardiometabolic health markers, including blood pressure, cholesterol, and A1C levels.

• Higher remission rates for prediabetes: In a clinical trial, a high percentage of patients with prediabetes achieved normal blood sugar levels while taking Cagrilintide combined with a GLP-1.